C 301Alternative Names: C-301; Valproic acid/taurine
Latest Information Update: 09 Jul 2007
At a glance
- Originator CepTor Corporation
- Mechanism of Action GABA uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 01 Mar 2005 Ceptor Corporation is now an independent company
- 20 Jan 2004 Preclinical trials in Epilepsy in USA (unspecified route)